Figure 2. The clinical outline of the patient.

We provided a clinical overview of the patient. After initiating treatment, we obtained the results of coagulation factor activity and the presence of an inhibitor and its titer. Throughout the treatment course, we sequentially suspected, differentiated, and diagnosed the patient's pathogenesis. The APTT remained prolonged and outside the normal range throughout the clinical course, even after FFP supplementation.

Alb, albumin; FFP, fresh frozen plasma; APTT, activated partial thromboplastin time